These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7789929)

  • 21. Latent reservoirs of HIV infection: flushing with IL-2?
    Cooper DA; Emery S
    Nat Med; 1999 Jun; 5(6):611-2. PubMed ID: 10371491
    [No Abstract]   [Full Text] [Related]  

  • 22. Failure to reconstitute CD4+ T-cells despite suppression of HIV replication under HAART.
    Aiuti F; Mezzaroma I
    AIDS Rev; 2006; 8(2):88-97. PubMed ID: 16848276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is cure possible for HIV?
    Scondras D
    AIDS Treat News; 2007; (422):6-7. PubMed ID: 17882783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV-1 dynamics in vivo: implications for therapy.
    Simon V; Ho DD
    Nat Rev Microbiol; 2003 Dec; 1(3):181-90. PubMed ID: 15035022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IL-2 taken to HAART.
    Gilden D
    GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hidden HIV reservoirs: will eradication of the virus be possible?
    Gomez E
    Newsline People AIDS Coalit N Y; 1998 Mar; ():18-9. PubMed ID: 11367451
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1-specific CD4+ T lymphocyte turnover and activation increase upon viral rebound.
    Scriba TJ; Zhang HT; Brown HL; Oxenius A; Tamm N; Fidler S; Fox J; Weber JN; Klenerman P; Day CL; Lucas M; Phillips RE
    J Clin Invest; 2005 Feb; 115(2):443-50. PubMed ID: 15668739
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of antiretroviral therapy on plasma HIV RNA.
    Saag MS
    J Biol Regul Homeost Agents; 1995; 9(3):105-6. PubMed ID: 8782017
    [No Abstract]   [Full Text] [Related]  

  • 29. Eliminating persistent HIV infection: getting to the end of the rainbow.
    Margolis DM; Archin NM
    J Infect Dis; 2007 Jun; 195(12):1734-6. PubMed ID: 17492587
    [No Abstract]   [Full Text] [Related]  

  • 30. Anti-HIV agents. Immunotoxins to the rescue.
    TreatmentUpdate; 2000 Jan; 11(10):1-2. PubMed ID: 12125631
    [No Abstract]   [Full Text] [Related]  

  • 31. No cure yet for HIV-1, but therapeutic research presses on.
    Schooley RT; Mellors JW
    J Infect Dis; 2007 Mar; 195(6):770-2. PubMed ID: 17299705
    [No Abstract]   [Full Text] [Related]  

  • 32. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection.
    Chun TW; Carruth L; Finzi D; Shen X; DiGiuseppe JA; Taylor H; Hermankova M; Chadwick K; Margolick J; Quinn TC; Kuo YH; Brookmeyer R; Zeiger MA; Barditch-Crovo P; Siliciano RF
    Nature; 1997 May; 387(6629):183-8. PubMed ID: 9144289
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic drugs--rarely causal therapy].
    Uhl D
    Med Monatsschr Pharm; 1990 May; 13(5):129. PubMed ID: 2192241
    [No Abstract]   [Full Text] [Related]  

  • 34. [AIDS. Therapeutic approaches in the control of HIV infection].
    Müller WE; Schröder HC
    Med Monatsschr Pharm; 1990 May; 13(5):141-6. PubMed ID: 2192245
    [No Abstract]   [Full Text] [Related]  

  • 35. Can HIV be cured?
    Stevenson M
    Sci Am; 2008 Nov; 299(5):78-83. PubMed ID: 18998350
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacologic regulation of HIV expression.
    Fauci AS
    AIDS Res Hum Retroviruses; 1992 May; 8(5):707-10. PubMed ID: 1515220
    [No Abstract]   [Full Text] [Related]  

  • 37. Chemotherapeutic interventions targeting HIV interactions with host-associated carbohydrates.
    McReynolds KD; Gervay-Hague J
    Chem Rev; 2007 May; 107(5):1533-52. PubMed ID: 17439183
    [No Abstract]   [Full Text] [Related]  

  • 38. Editorial: CD4+ T cells in HIV: A Friend or a Foe?
    Govindaraj S; Babu H; Kannanganat S; Vaccari M; Petrovas C; Velu V
    Front Immunol; 2023; 14():1203531. PubMed ID: 37497218
    [No Abstract]   [Full Text] [Related]  

  • 39. Normal physiology and HIV pathophysiology of human T-cell dynamics.
    Richman DD
    J Clin Invest; 2000 Mar; 105(5):565-6. PubMed ID: 10712427
    [No Abstract]   [Full Text] [Related]  

  • 40. Promising anti-HIV compounds in preclinical or early clinical development.
    Litterst C
    Adv Exp Med Biol; 1996; 394():397-404. PubMed ID: 8815704
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.